Glaucoma Quality of Life-15
- Introduced by
- Nelson PA, Aspinall PA et al.
- Year
- 1998
- Type
- Self-report
- Family
- glaucoma-specific quality of life
What does it do?
The GQL-15 is a 15-item, disease-specific quality of life questionnaire designed to measure the impact of glaucoma on patients' daily functioning and psychological well-being.
Developed by Nelson, Aspinall, and colleagues in the UK (1998), the GQL-15 emphasizes glaucoma-specific concerns—visual field loss, peripheral vision, lighting sensitivity, and falls risk—making it a sensitive complement to generic or broader vision-related instruments in glaucoma populations.
The intuition behind the method
Glaucoma causes insidious, irreversible peripheral vision loss, often without patient awareness until substantial damage has occurred. Generic vision measures may miss the unique burden of glaucoma: difficulty navigating in dim light (slower rod function), increased fall risk from undetected obstacles in peripheral field, and anxiety about progressive blindness. The GQL-15 directly addresses these concerns, capturing both functional limitation and emotional/psychological impact specific to glaucoma. It helps clinicians understand how a patient perceives their disease risk and disability, which drives adherence to long-term treatment.
History
Developed by Nelson, Aspinall, O'Brien, and colleagues at the University of Aberdeen, UK (1998). Originated as a focused response to the need for a glaucoma-specific QoL measure shorter than and complementary to generic instruments. Published in Br J Ophthalmol 1998. Revised versions and cross-cultural adaptations have been developed; the core 15-item structure remains the reference standard. Increasingly adopted in European glaucoma trials and clinics; less widely used in the US compared to NEI-VFQ-25.
When to use it
Ideal for glaucoma patients across all severity stages—mild suspected glaucoma, established disease, advanced glaucoma—to understand subjective burden and inform shared decision-making about treatment intensity. Particularly valuable when VA is normal but visual field loss is advancing, or when IOP is well-controlled but patient anxiety remains high. Recommended at baseline, at 6–12 month intervals during treatment, and after any major intervention. Helps distinguish glaucoma anxiety from true functional impairment.
Limitations and considerations
- Relatively short instrument may miss nuanced QoL domains (e.g., color vision, near vision, hobbies); not multidimensional like NEI-VFQ-25
- Limited translation and validation outside English-speaking populations; less extensively studied than VFQ-25 in international cohorts
- Does not distinguish among different causes of QoL loss (e.g., side effects vs. disease vs. comorbidities); clinician judgment required
- Validation primarily in UK/European populations; applicability to other ethnic groups and healthcare systems less established
- No subscales; cannot pinpoint whether patient's QoL loss is driven by visual, mobility, lighting, or emotional factors
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Disease-specific: directly addresses peripheral field loss, falls risk, and lighting difficulty unique to glaucoma; more targeted than generic vision instruments
- Validated in glaucoma populations: strong internal consistency (Cronbach α ~0.85), test-retest reliability (ICC >0.75), and sensitivity to glaucoma severity and progression
- Brief and practical: 15 items completed in 5 minutes, suitable for routine clinical use and busy practices
- Predictive of real-world risk: GQL-15 scores correlate with actual falls, driving cessation, and future visual disability in glaucoma cohorts
- Simple scoring: single global score (0–100); no complex algorithm; easily tracked over time in electronic health records
How it works
How it works
15 items covering visual function, mobility, lighting, reading, and emotional domains specific to glaucoma. Respondents rate each item on a 5-point Likert scale (ranging from 'not at all' to 'all of the time' or similar anchors). Administration takes 5–8 minutes. Suitable for adults aged 18+ with glaucoma diagnosis. Can be self-completed, interviewer-administered, or completed via telephone with minimal differences in response patterns.
Each item is scored 1–5 points. Total raw score ranges from 15 to 75. This is then converted to a 0–100 scale using the formula: (raw score − 15) / 60 × 100. Lower converted scores = better QoL; higher scores = greater glaucoma-related disability. Subscale scoring is not standard; the GQL-15 is typically reported as a single global measure. Minimal Clinically Important Difference (MCID) is approximately 5–10 points on the 0–100 scale.
Scores on 0–100 scale: 0–20 = minimal/no glaucoma-related QoL impact (excellent QoL); 21–40 = mild impact; 41–60 = moderate impact; 61–80 = substantial impact; 81–100 = severe glaucoma-related QoL loss/disability. Comparison to age-matched or diagnosis-matched reference populations contextualizes individual results. Longitudinal tracking (baseline, 3–6 month, annual) reveals whether disease progression or treatment side effects erode QoL. Worsening GQL-15 despite stable VA/VF suggests disease anxiety or functional decline not captured by objective measures.
Glaucoma severity staging alongside IOP and visual field: GQL-15 captures patient-perceived burden, improving completeness of disease assessment Treatment monitoring and medication adherence assessment: medication side effects (tearing, redness, eye discomfort) often reduce QoL more than the disease itself; GQL-15 detects this Pre- and post-operative assessment in glaucoma surgery (trabeculectomy, MIGS, valve placement) to document functional and emotional outcomes Clinical trials of new glaucoma therapies: primary or secondary endpoint quantifying patient benefit beyond IOP reduction alone
Common pitfalls
- Assuming GQL-15 replaces visual field or IOP monitoring: it is complementary, not substitutive. A patient with worsening field loss but stable high GQL-15 score may be adapting but still at risk of future functional decline.
- Using GQL-15 alone to guide treatment intensity in newly diagnosed or mild glaucoma: objective IOP targets and family history should drive decisions, not QoL alone
- Over-attributing GQL-15 decline to glaucoma when comorbid depression, other eye disease, or medication side effects are present: multifactorial assessment required
- Neglecting to convert raw score (15–75) to 0–100 scale in some analyses, leading to misinterpretation of published benchmarks
Frequently asked questions
How does GQL-15 differ from the NEI-VFQ-25 in glaucoma patients?
GQL-15 is glaucoma-specific with items on peripheral vision, falls, and lighting difficulty; VFQ-25 is broader, covering distance, near, driving, and other vision domains across all eye conditions. In glaucoma, GQL-15 is often more sensitive to disease-specific burden; VFQ-25 may be less sensitive if peripheral field loss has not yet reduced reading or driving. Both are valid; many trials use both for comprehensive assessment.
What is the score scale, and what does a change of 10 points mean?
GQL-15 is converted to a 0–100 scale (lower = better QoL). A change of 5–10 points is considered clinically meaningful. For example, improvement from 45 to 35 after successful glaucoma surgery indicates substantial QoL gain; worsening from 30 to 50 may signal disease progression or medication side effects warranting intervention adjustment.
Can GQL-15 be used in advanced glaucoma or near-total visual field loss?
Yes. Even in advanced stages, GQL-15 captures remaining functional difficulty, anxiety about further loss, and mobility/falls risk. However, floor effects may occur in blindness, where most items score near maximum (worst). In such cases, qualitative assessment or low-vision specific instruments complement GQL-15.
Is GQL-15 free to use, and what are licensing requirements?
GQL-15 is not proprietary and is freely available for clinical and research use. No licensing or payment required. Always cite Nelson et al. (1998) in publications. Versions in multiple languages exist with varying validation status; check the literature for your target language.
Related methods
Sources
Nelson, P., Aspinall, P. A., Papasthathis, K., et al. (1998). Quality of life in glaucoma and its relationship with visual function. J Glaucoma, 7(2), 71-78.
Open publication referenceCopied.Nelson, P., Aspinall, P. A., O'Brien, C. (1998). Screening for glaucoma with the Glaucoma-15. Br J Ophthalmol, 82(4), 327-334.
Open publication referenceCopied.